It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus.
Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients With Chronic Relapsing Pemphigus: BELIEVE Phase II Study (Part A)’ was presented at the AAD VMX, 23-25 April 2021.
- What is the rationale for the use of BTK inhibitors in pemphigus? (0:05)
- What were the aims, design and patient population of the BELIEVE study? (0:51)
- What were the efficacy and quality of life endpoints of the study and how well were these achieved? (2:10)
- What were the safety and tolerability findings of the study? (3:18)
- What future studies are planned? (4:14)
Disclosures: Prof. Dedee Murrell has acted and an investigator and advisor for Principia-Sanofi, ArgenX, Roche-Genentech and Eli Lilly. Prof. Murrell is also the co-inventor of the PDAI and ABQOL measures.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Dermatological Diseases
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!